Group 1 - The core point of the article is that Dongcheng Pharmaceutical's subsidiary, LNC PHARMA PTE. LTD., has received FDA approval for a clinical trial of the drug 225Ac-LNC1011, which is intended for treating advanced prostate cancer patients with PSMA-positive expression [1] Group 2 - The clinical trial is set to begin shortly, indicating progress in the development of this potential treatment [1]

Core Viewpoint - Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials [1][2]. Drug Information - The drug 225Ac-LNC1011 is an injectable formulation intended for the treatment of advanced prostate cancer expressing Prostate Specific Membrane Antigen (PSMA) [2]. - The drug utilizes alpha particle radiation therapy, which has a short range (<100 μm) and high energy deposition (80-100 keV/μm), providing stronger cell-killing effects on tumors while minimizing damage to surrounding healthy tissues [2]. - Previous animal and human trials have shown excellent pharmacokinetic properties and significant efficacy, indicating its potential as a more effective PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC) [2]. Financial Investment - The total research and development expenses incurred for the 225Ac-LNC1011 project to date amount to approximately 14.1648 million yuan [3].

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, with Phase I trials to commence shortly [1] Group 1 - The FDA issued a Study May Proceed Letter (SMP) for the clinical trial of 225Ac-LNC1011 injection [1] - The clinical trial is set to begin in the near future [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary LNC PHARMA PTE.LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials for treating advanced prostate cancer patients with PSMA-positive expression [1] Company Summary - Dongcheng Pharmaceutical's subsidiary, LNC PHARMA PTE.LTD., has been granted FDA approval for a clinical trial [1] - The drug 225Ac-LNC1011 is intended for the treatment of advanced prostate cancer patients [1] Industry Summary - The approval of 225Ac-LNC1011 marks a significant step in the development of targeted therapies for prostate cancer [1] - The focus on PSMA-positive expression in advanced prostate cancer highlights the industry's trend towards precision medicine [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials [1] Summary by Relevant Sections - **FDA Approval**: The FDA has completed the safety review of the 225Ac-LNC1011 injection application and has issued a Study May Proceed Letter (SMP), allowing the proposed prostate cancer clinical study to move forward [1] - **Next Steps**: Following the issuance of the SMP, the 225Ac-LNC1011 injection must undergo clinical trials and receive FDA review and approval before it can be marketed and sold in the United States [1]

证券代码：002675 证券简称：东诚药业 公告编号：2025-046 现将 225Ac-LNC1011 注射液相关情况公告如下： | 药物名称 | 注射液 225Ac-LNC1011 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | IND 号 | 175370 | | 审批结论 | 已完成对 注射液申请的安全性审核， FDA 225Ac-LNC1011 | | | 并认为可以继续进行拟议的前列腺癌临床研究。 | 一、药物的基本情况 二、药物的其他情况 烟台东诚药业集团股份有限公司 关于下属公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2025 年 8 月 22 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 下属公司 LNC PHARMA PTE. LTD. （以下简称"蓝纳成药业"）收到美国食品 药品监督管理局（以下简称"FDA"）核准签发的关于 225Ac-LNC1011 注射液的 药品临床试验批准通知书 (Study May Proceed Letter，以下简 ...

Group 1 - The second National Pharmacy Discipline High-Quality Development Forum was held in Yantai from August 20 to 22, gathering over 300 experts, scholars, and representatives from pharmaceutical companies to discuss new paths and directions for high-quality development in the pharmacy discipline [1][2] - The forum focused on "AI Empowering Biomanufacturing: Cross-Innovation in Pharmacy Discipline and Empowering Industrial Development," featuring special reports from academicians on topics such as pharmacokinetics and pharmacodynamics of gene and cell drugs, and new models for biopharmaceutical discipline development [4] - A total of 44 presentations were made across seven sub-forums covering various topics in pharmacy, aiming to foster discussions on innovative talent cultivation and collaborative education models [4] Group 2 - Yantai University established the Excellence Engineer College, marking a significant step in reforming talent cultivation models in the biopharmaceutical field [7] - The rapid development of Yantai University's pharmacy discipline reflects the unique characteristics of the Yantai biopharmaceutical industry, which includes notable companies like Green Leaf Pharmaceutical and Rongchang Biopharmaceutical [8][10] - As of June this year, Yantai has 274 key enterprises in the biopharmaceutical and health industry, with 146 of them being above-scale enterprises, contributing to a comprehensive development pattern that includes biopharmaceuticals, chemical drugs, modern traditional Chinese medicine, and medical devices [10][11]

Group 1 - The actual controller of Yantai Dongcheng Pharmaceutical Group Co., Ltd., Mr. You Shouyi, has notified the company about the extension of the pledge of part of his shares [1] - As of August 21, 2025, Mr. You holds 103,305,678 shares of Dongcheng Pharmaceutical, with a total of 28,578,000 shares pledged, accounting for 27.66% of his total holdings [1] - The overall risk of share pledge is controllable, and there is currently no risk of forced liquidation [1][4] Group 2 - The actual controller and his concerted actors have a good credit status and possess the financial capability to repay, thus there is no risk of forced liquidation or transfer of control [4] - The company will continue to monitor the pledge situation and will disclose relevant information in a timely manner as required [4]

Group 1 - The core business of Dongcheng Pharmaceutical is entirely focused on the biopharmaceutical industry, with a revenue composition of 100% from this sector for the first half of 2025 [1] Group 2 - Dongcheng Pharmaceutical announced on August 21 that its actual controller, Mr. You Shouyi, has pledged part of his shares for extension. As of August 21, 2025, he holds approximately 103 million shares of Dongcheng Pharmaceutical, with a total of about 28.58 million shares pledged, accounting for 27.66% of his total holdings. The overall risk of share pledge is manageable, and there is currently no risk of forced liquidation [3]

Core Insights - The company reported a decline in revenue and net profit for the first half of 2025, with total revenue at 1.384 billion yuan, down 2.6% year-on-year, and net profit attributable to shareholders at 89 million yuan, down 20.7% [1] Financial Performance - Revenue for the nuclear medicine segment reached 503 million yuan, a year-on-year increase of 0.78%, with a gross margin of 67.27% [2] - The core product, 18F-FDG, generated revenue of 212 million yuan, reflecting an 8.72% increase year-on-year [2] - The raw material drug segment reported revenue of 611 million yuan, down 7.02%, primarily due to a decline in heparin sodium sales prices [2] Development Trends - The company has invested in 7 operational nuclear pharmacies focused on single-photon drugs and 22 on positron emission drugs, with 31 nuclear drug production centers currently in operation [2] - The company’s innovative nuclear drug pipeline is progressing, with the approval of sodium fluoride [18F] injection in May 2025 and ongoing clinical trials for several other products [3] Profit Forecast and Valuation - The company maintains its EPS forecast for 2025 and 2026 at 0.32 yuan and 0.40 yuan, respectively, with the current stock price corresponding to a P/E ratio of 55.1 times for 2025 and 43.9 times for 2026 [4] - The target price has been raised by 16.4% to 19.2 yuan, indicating an 8.8% upside potential from the current stock price [4]